Why the study?
Does the peptide-based renin inhibitor A-72517 demonstrate oral bioavailability and efficacy in reducing blood pressure and renin activity in animal models?
Population
Animal models including monkey, rat, ferret, and conscious, salt-depleted dogs
Design
Preclinical
Authors
Loading...
Animal data support oral renin inhibitor feasibility; hypothesis-generating for humans and should not yet change practice.
Does the peptide-based renin inhibitor A-72517 demonstrate oral bioavailability and efficacy in reducing blood pressure and renin activity in animal models?
This preclinical study demonstrates that a peptide-based renin inhibitor can achieve significant oral bioavailability and physiological efficacy, supporting the development of oral peptide-based therapeutics.
Kleinert et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: